Supriya Lifescience Intrinsic Value
Supriya Lifescience (SUPRIYA) median intrinsic value is ₹1105.00 from 10 valuation models (range ₹272–₹1813), vs current price ₹906.30 — +21.9% upside (Trading Below Calculated Value), margin of safety 18.0%. See SUPRIYA price to book ratio to compare market price against book value per share.
SUPRIYA Valuation Methods Summary — DCF, Graham Number & P/E
Supriya Lifescience intrinsic value across 10 models vs current price ₹906.30 — upside/downside and value range per method. For current market price and key ratios, visit SUPRIYA share price.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹543.40 | ₹434.72 - ₹652.08 | -40.0% | EPS: ₹24.70, Sector P/E: 22x |
| Book Value Method | asset | ₹1497.50 | ₹1347.75 - ₹1647.25 | +65.2% | Book Value/Share: ₹748.75, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1105.00 | ₹994.50 - ₹1215.50 | +21.9% | Revenue/Share: ₹552.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1812.60 | ₹1631.34 - ₹1993.86 | +100.0% | EBITDA: ₹301.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1579.06 | ₹1263.25 - ₹1894.87 | +74.2% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹395.20 | ₹355.68 - ₹434.72 | -56.4% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹398.29 | ₹358.46 - ₹438.12 | -56.1% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹1732.50 | ₹1559.25 - ₹1905.75 | +91.2% | ROE: 16.5%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹645.07 | ₹580.56 - ₹709.58 | -28.8% | EPS: ₹24.70, BVPS: ₹748.75 |
| Dividend Yield Method | dividend | ₹271.89 | ₹244.70 - ₹299.08 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
SUPRIYA Intrinsic Value vs Market Price — All Valuation Models
Supriya Lifescience fair value range ₹272–₹1813 vs current market price ₹906.30 across 10 valuation models. Check Supriya Lifescience market cap to track the company's total market size over time.
SUPRIYA Intrinsic Value Analysis — Undervalued or Overvalued?
Supriya Lifescience median intrinsic value ₹1105.00, current price ₹906.30 — Trading Below Calculated Value by 21.9%, margin of safety 18.0%.
What is the intrinsic value of SUPRIYA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Supriya Lifescience (SUPRIYA) is ₹1105.00 (median value). With the current market price of ₹906.30, this represents a +21.9% variance from our estimated fair value.
The valuation range spans from ₹271.89 to ₹1812.60, indicating ₹271.89 - ₹1812.60.
Is SUPRIYA undervalued or overvalued?
Based on our multi-method analysis, Supriya Lifescience (SUPRIYA) appears to be trading below calculated value by approximately 21.9%.
SUPRIYA Financial Health — Key Ratios vs Industry Benchmarks
Supriya Lifescience financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SUPRIYA Cash Flow Quality — Operating & Free Cash Flow
Supriya Lifescience operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹186 Cr | ₹98 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹165 Cr | ₹89 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹26 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹64 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹49 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |